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Abstract
Introduction: There are four endemic serotypes of human coronavirus (HCoV) that may cause 
community-acquired pneumonia (CAP) in humans.  The clinical syndrome of CAP due to HCoVs 
is not well characterized.  The objectives of this study were to evaluate incidence, epidemiology, 
and outcomes of CAP in adults due to HCoV and to compare them to CAP due to influenza.
Methods: The Louisville Pneumonia Study (LPS) is a prospective observational study of hos-
pitalized adult patients with CAP in the city of Louisville.  Patients enrolled in the LPS in whom 
a respiratory viral panel polymerase chain reaction (PCR) was obtained were evaluated.  Inci-
dence, epidemiology, and outcomes were compared for patients with a positive PCR for HCoV 
versus patients with a positive PCR for influenza.
Results: From 1,974 CAP patients with a PCR performed, HCoV was identified in 65 patients 
(3.3%), corresponding to the following serotypes: HCoV-229E in 12 patients, HCoV-OC43 in 
38 patients, HCoV-NL63 in 6 patients and HCoV-HKU1 in 9 patients.  No differences were 
observed for clinical presentation and early outcomes for patients with CAP due to HCoV when 
compared to 244 patients with CAP due to influenza.  One-year mortality after hospitalization 
was 32% for patients with CAP due to HCoV versus 13% for patients with CAP due to influenza. 
Conclusions: When compared to patients with CAP due to influenza, the clinical presentation 
of patients with CAP due to HCoV is similar, but these patients have significantly worse out-
comes one year after hospitalization.
Introduction
Community-acquired pneumonia (CAP) causes significant morbidity and causes more 
deaths in the US than any other infectious disease.[1] Approximately 23% percent of CAP 
is attributed to viruses.[2] That figure is made up of multiple viruses including: human 
rhinovirus, influenza A and B viruses, respiratory syncytial virus, parainfluenza virus 
types 1, 2, and 3, and coronaviruses 229E, OC43, NL63, and HKU1 among others. Present-
ly, there is an interest in CAP due to the Coronoviridae family. Clinical aspects of the dis-
ease are well described in children, but not adults, especially with CAP. The Middle East 
Respiratory Syndrome (MERS-CoV), severe acute respiratory syndrome (SARS-CoV), 
and now the novel 2019 coronavirus (SARS-CoV-2) are well known, and fortunately not 
endemic like the others.  
Coronaviruses are enveloped, single-stranded RNA viruses characterized by club-like 
spikes that project from their surface.  Genera that can cause human disease include 
alphacoronaviridae and betacoronaviridae.  Endemic strains of human coronavirus 
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(HCoV) include -229E, -OC43, -NL63 and -HKU1.  These strains are associated mainly with illnesses of the upper 
respiratory and gastrointestinal tracts consistent with a common cold.  Approximately 90% of epidemiological data is 
from samples obtained from children; it exhibits winter seasonality, a prevalent strain that varies year to year, and at 
least one strain, HCoV-OC43, that has a higher correlation with infections of the lower respiratory tract.[3,4] There is 
minimal existing data of adults with CAP due to HCoV.  On the other hand, the clinical course of influenza with CAP 
and its outcomes have been well described, so it serves as a familiar infection to which HCoV with CAP may be com-
pared.  
In Louisville, KY, nasopharyngeal specimens were collected as standard of care for viral testing over three years in 
adult patients admitted with CAP.[5] Among those specimens were patients with viral infections, including influenza 
virus and HCoV.  From those data, we sought to evaluate incidence, epidemiology, and outcomes of hospitalized adults 
with CAP due to endemic HCoV and compare them to CAP due to influenza virus.
Methods
This was a secondary analysis of adult patients from the Louisville Pneumonia Study; a large prospective popula-
tion-based cohort study of hospitalized adults with CAP aged ≥18 years in Louisville, Kentucky.  The primary study was 
performed in all nine adult acute-care hospitals in Louisville over three years, from June 1, 2014 to May 31, 2016 and 
from October 1, 2016 to March 31, 2017.  It included 7,449 patients and defined incidence, epidemiology, and mortality 
of adult patients hospitalized with CAP in an entire city.[5] The study was exempt from informed consent.  Both studies 
were approved by the research offices at each participating hospital, and by the Institutional Review Board (IRB num-
ber 11.0615).
Patients meeting screening requirements were further screened using the following inclusion criteria: positive lung 
imaging for CAP by chest radiograph or chest computed tomography plus one clinical criterion addressing cough, tem-
perature or white blood cell count.[5] Patients with HCoV or influenza presented once in the study period.  Multiple 
co-infections were acceptable for inclusion, with the exception of HCoV and influenza viruses together.  Exclusion 
criteria were as follows: non-Louisville residency, incarceration, a diagnosis of pneumonia more than 72 hours after 
admission, a lack of a social security number and laboratory tests positive for both HCoV and influenza virus in the 
same patient.  
Variables evaluated in the medical record at the time of enrollment are in Table 1.  Pneumonia severity was measured 
using the pneumonia severity index.  The four endemic strains HCoV-229E, -OC43, -NL63 and -HKU1, as well as in-
fluenza A and B, were detected by routine standard of care from a nasopharyngeal swab.  Time to clinical stability was 
followed up to seven days as defined previously.[6] It required attaining four clinical criteria.  Length of hospital stay 
was calculated by subtracting the date of admission from the date of discharge up to 14 days; after that time-period, 
length of stay was censored in an effort to capture length of stay only related to CAP.  All-cause mortality was measured 
as in-hospital, 30-day, 6-month and 1-year.
Continuous variables were reported as medians and interquartile ranges. Categorical variables were reported as fre-
quencies and percentages.  Mann-Whitney U tests and Chi-Squared tests were used to compare baseline character-
istics between groups where appropriate.  A Kaplan-Meier curve for time to mortality was produced.  Survival times 
were compared using log-rank tests.
Results
Patients that had PCR viral tests performed in the study totaled 1,974.  Among the excluded patients, one tested posi-
tive for both HCoV and influenza.  Sixty-five patients had HCoV, and 244 had influenza virus.  There were 23 HCoV 
patients with a co-infection and 45 influenza patients with a co-infection.(Figure 1) Serotypes identified in the 65 pa-
tients included: 229E in 12 patients, OC43 in 38 patients, NL63 in 6 patients, and HKU1 in 9 patients.
Epidemiology
The median age for patients with HCoV was 69 years, and with influenza was 68 years.(Table 1)  The distribution of 
patients by age was highest for ages ≥65 years.(Figure 2)  Female patients comprised 53% of patients with HCoV, and 
57% of patients with influenza.  Comorbidities were similar in both groups with four exceptions that were small, but 
statistically significant: body mass index (BMI), temperature, platelet count and white blood cell count.(Table 1)  The 
proportion with two or greater comorbidities was 57% in both groups.  More viral tests were performed during winter 
months, November to March, and the incidences for HCoV and influenza were higher during that time.(Figure 3)
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Variable Coronavirus Influenza P
Total no. 65 244  
Demographics
Age, median [IQR] 69 [52, 79] 68 [56, 79] 0.607
Sex: Male, Frequency (%) 28 (43) 115 (47) 0.658
Race, Frequency (%) 0.078
Black 7 (11) 51 (21)  
White 58 (89) 188 (77)  
Other 0 (0) 5 (2)  
Current Smoker 16 (25) 72 (30) 0.534
Nursing Home Resident (%) 5 (8) 21 (9) >0.999
Comorbidities Frequency (%)
HIV 0 (0) 5 (2) 0.542
Neoplastic disease 11 (17) 23 (9) 0.135
Congestive Heart Failure 12 (18) 56 (23) 0.543
Cerebrovascular Disease 10 (15) 23 (9) 0.248
Cirrhosis 1 (2) 5 (2) >0.999
Liver Disease 4 (6) 14 (6) >0.999
Renal Disease 14 (22) 65 (27) 0.498
Diabetes 19 (29) 82 (34) 0.603
COPD 25 (38) 108 (44) 0.485
BMI, median [IQR] 25 [22, 29] 28 [23, 33] 0.035
Obesity (BMI > 30) 15 (23) 89 (36) 0.060
Laboratory and Physical Findings Median [IQR] 
Temperature (°C) 37 [37, 39] 38 [37, 39] 0.010
Diastolic blood pressure (mm Hg) 58 [49, 69] 57 [48, 66] 0.767
Systolic Blood Pressure (mm Hg) 115 [103, 131] 118 [100, 132] 0.844
Respiratory Rate (breaths/minute) 23 [20, 28] 22 [20, 27] 0.599
Heart Rate (beats/minute) 108 [94, 122] 104 [91, 118] 0.268
Serum Glucose (mg/dL) 144 [117, 197] 139 [113, 187] 0.393
Platelets per 1000/μL 231 [173, 282] 184 [152, 238] 0.002
Serum creatinine (mg/dL) 1 [1, 1] 1 [1, 1] 0.166
Serum Potassium (mEq/L) 4 [4, 4] 4 [4, 4] 0.304
Serum sodium (mEq/L) 136 [134, 140] 136 [134, 140] 0.897
Blood Urea Nitrogen (mg/dL) 17 [13, 23] 18 [13, 26] 0.929
WBC per 1000/μL 12 [10, 17] 9 [6, 13] <0.001
Hemoglobin (g/dL) 12 [11, 13] 12 [11, 13] 0.691
Hematocrit (%) 36 [32, 39] 37 [33, 41] 0.356
Severity of Disease (on admission) Frequency (%)
Ventilatory Support 4 (6) 23 (9) 0.560
Vasopressors 2 (3) 5 (2) 0.979
PSI Risk Class IV/V 40 (62) 133 (55) 0.382
Altered Mental Status 11 (17) 37 (15) 0.877
Direct Admission to the ICU 12 (18) 30 (12) 0.278
COPD, chronic obstructive pulmonary disease; HIV, human immunodeficiency virus; ICU, intensive care unit; IQR, 
interquartile range; PSI, pneumonia severity index; WBC white blood cell count
Table 1. Characteristics of hospitalized adults admitted with community-acquired pneumonia with a positive 
test for either endemic human coronavirus or influenza virus.  Frequency with percent or median with the 
interquartile range is used as marked accordingly.
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Figure 2. Characteristics of hospitalized adults admitted with community-acquired pneumonia 
with a positive test for either endemic human coronavirus or influenza virus.
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Figure 1. The proportion of each type of co-infection among hospitalized adults admitted with 
community-acquired pneumonia with either endemic coronavirus or influenza.
Imaging 
A representative chest radiograph of a patient with CAP due to HCoV showed a lobar infiltrate.(Figure 4)  Older adults 
with comorbidities, such as chronic obstructive pulmonary disease, and a co-infection had infiltrates concomitant with 
chronic lung disease.(Figure 4)
Outcomes
No differences in early outcomes were found.(Table 2)  For the entire population, the median time to clinical stability 
was 2 days with an interquartile range (IQR) of 1-4 days, and the length of stay was 4 days with an interquartile range 
of 3-7 days.  Mortality was higher in those with influenza for in-hospital and 30-day mortality (P>0.05), while it was 
higher in those with HCoV for 6-month (P>0.05) and 1-year mortality (P=0.041).(Table 2)  One-year survival is shown 
in Figure 5, with significant differences in survival found between the two groups (P=0.048).
Discussion
Our data showed that outcomes, including time to clinical stability, length of stay and mortality up to six months were 
similar to influenza, but the 1-year mortality was statistically different with 32% among HCoV patients and 17% among 
influenza patients.  The reason for this difference in mortality is unknown; however, it is clear that the Coronaviridae 
family, including MERS-CoV, SARS-CoV and SARS-CoV-2, has the potential to cause significant morbidity and mor-
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tality.  The incidence of HCoV CAP in our study was 3.6%.  This figure is similar to what has been reported in the liter-
ature.[2,7]
Demographics were similar overall as well with most cases occurring in patients >65 years and in 57% having at least 
two comorbidities.  There were a few statistically significant differences, including temperature, platelet count, white 
blood count, and body mass index, but the difference in platelet count between each group was not clinically signifi-
cant.  
For patients admitted with CAP, there did not appear to be any clinically discernable difference when considering a 
patient’s hospital course, but this data reveals that a difference was found compared to influenza among patients after a 
year had passed.  Physicians and other primary care professionals should be aware of the long-term consequences that 
a seemingly innocuous HCoV may have later for patients, especially if they are older or have comorbidities.  
Most publications regarding adults with CAP due to HCoV are case reports or a series of ten or fewer patients. Al-
though studies exist with larger sample sizes tested, all reported similarly small numbers of positive patients.[8-20]
(Table 3) In one study of patients with CAP, 254 viral PCR tests were performed and only seven patients were positive 
for HCoV.[17] In another study of patients with lower respiratory tract infections, 3,104 viral PCR tests were performed 
and only six patients were positive for HCoV.[21] Two studies included other potentially relevant patients, but children 
and adults were reported together in one study and rhinovirus and HCoV were reported together in another study.
[22,23] Overall, 52 cases have been reported until this study; six of whom died.
Patient characteristics for adults with CAP due to viral etiologies in general have been described. In a study of 78 pa-
tients with suspected CAP and a positive viral PCR test, the most common viruses were influenza (35%), rhinovirus 
(26%), RSV (9%), and coronavirus (9%).[17] The median patient age was 60 and the predominant clinical features were 
Figure 3. The incidences of endemic human coronavirus and influenza during each month of the 
three-year study for hospitalized adults admitted with community-acquired pneumonia.
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(a)
(b)
Figure 4. A representative chest radiograph of a 64-year-old female hospitalized with community-acquired 
pneumonia with a test positive for endemic human coronavirus (no co-infection) (a) and a similar patient, 
but who had chronic obstructive pulmonary disease (b).
Variable Coronavirus Influenza P
Total no. 65 244  
Time to clinical stability (median [IQR]) 3 [1, 5] 2 [1, 4] 0.152
Hospitalized length of stay (median [IQR]) 5 [3, 8] 4 [3, 8] 0.621
In-hospital mortality (%) 1 (2) 10 (4) 0.540
30-day mortality (%) 3 (5) 21 (9) 0.418
6-month mortality (%) 14 (22) 31 (13) 0.134
1-year mortality (%) 19 (32) 39 (17) 0.041
IQR, interquartile range
Table 2. Outcomes of hospitalized adults admitted with community-acquired pneumonia with a positive test 
for either endemic human coronavirus or influenza.  Frequency with percent or median with the interquartile 
range is used as marked accordingly.
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Figure 5. In patients with community-acquired pneumonia, Kaplan-Meier curves for time to mortality over 
one year were compared between those with endemic human coronavirus and influenza.
Study Year Country no. cases HCoV strain Deaths
Folz et al. [7] 1999 Durham, NC 1 - 0
Falsey et al. [8] 2002 Rochester, NY 2 - -
van Elden et al. [9] 2002 Netherlands 1 - 0
van Elden et al. [10] 2004 Netherlands 2 - -
Woo et al. [11] 2005 China 9 HKU1 2
Johnstone et al. [12] 2008 Canada 4 OC43 -
Oosterhof et al. [13] 2010 Denmark 1 NL63 1
van Gageldonk et al. [14] 2013 Netherlands 6 - -
Zhan et al. [15] 2014 China 2 OC43 0
Das et al. [16] 2015 France 6 (a) not HKU1 -
Mayer et al. [17] 2016 Germany 1 NL63 1
Galante O et al. [18] 2016 Israel 1 NL63 1
Pianana et al. [19] 2017 Spain 7 (b) OC43, NL63 1
Ieven et al. [20] 2018 11 European countries 6 - -
Arnold et al. 
(Present study) 2020 Louisville, KY 65
229E, OC43,
NL63, HKU1 3 (c)
a. Five definite cases, one probable and one possible.
b. Three confirmed cases due to NL63, and four possible due to OC43.
c. 30-day mortality.
Table 3.  Manuscripts identifying cases of adult patients hospitalized for community-acquired pneumonia 
with endemic human coronavirus.
ULJRI | https://doi.org/10.18297/jri/vol4/iss1/1 8
ULJRI Endemic Human Coronaviruses in Hospitalized Adults with Community-Acquired Pneumonia in the City of Louisville, Kentucky
cough (92%), dyspnea (74%), sputum production (62%), and fever (36%).  The most common underlying comorbidity 
was chronic lung disease, with 27% of the patients affected.  Comparatively, in the nine adults with CAP due to HCoV-
HKU1 described by Woo et al,  the mean age was slightly older at 71 and the predominating symptoms were again fever 
(80%), cough (70%), sputum production (60%), and dyspnea (60%).[12] Seven of the nine patients had underlying 
comorbidities with three patients having underlying lung disease.  Notably, two of the nine patients did die, and both 
had severe underlying comorbidities including malignancy.  Overall, the patient characteristics were essentially clini-
cally indistinguishable from other CAP illnesses.  
One limitation of the present study was that viral PCR panels were obtained primarily during the winter seasons as 
standard of practice.  Another limitation of the study was that co-infections might bias the comparisons between 
groups.  One strength of the present study was that it nearly doubled the number of cases of HCoV CAP reported in the 
literature, providing a significant contribution to the epidemiology of the disease.
  
In conclusion, HCoV is found in 3% of patients hospitalized for CAP.  The clinical presentation is similar to CAP caused 
by influenza.  It is unclear, however, why patients with HCoV CAP have twice the one-year mortality compared to those 
with influenza CAP.
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